Biologics, small molecules, steroids, biosimilars, approvals, and treatment access updates.
Page 15 of 15 · 706 articles
An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can...
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
This provides a new FDA‑approved biologic option (mirikizumab/Omvoh) for adults with moderate–severe Crohn's disease, including people who did not respond to prior therapies. The approval was based on Phase 3 trial...
FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...
Cure8 found this source from markets.businessinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full...
Cure8 could only read part of this source from gurufocus.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...
A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.
Cure8 could only read part of this source from patientcareonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from firstwordpharma.com.
Cure8 could only read part of this source from endpts.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full details.
Cure8 found this source from investor.lilly.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Mirikizumab, and IL-23 inhibitor. Open the original article for the full details.
Cure8 found this source from wsj.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Medications. Open the original article for the full details.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
Cure8 found this source from reuters.com, but the page could not be read reliably yet. It is tagged for Medications. Open the original article for the full details.
This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The...
Patients with Crohn’s disease and other IBD forms may see new research directions aimed at blocking immune cell proliferation by targeting nucleotide metabolism. This is early-stage, preclinical work presented at a...
Perianal fistulas are serious, hard-to-treat complications in pediatric Crohn disease. The study suggests starting anti-TNFα therapy early — especially for kids with perianal lesions — may lower the chance of developing...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Vedolizumab, and Anti Integrin. The original article is from msn.com.
Based on the title and source metadata, this appears to be an observational study related to Crohn's disease and Medications. The original article is from msn.com.
Cure8 found this source from ktbs.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
Fatigue is common in people with Crohn’s disease and ulcerative colitis and can persist even when standard measures say the disease is in remission. This study suggests stricter definitions of remission don’t necessarily...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease and Medications. The original article is from msn.com.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from webmd.com.
If your Crohn’s gets worse, your care plan may change — from new medicines to nutritional support or surgery — and this article summarizes common steps doctors take to prevent complications and control inflammation.
Postoperative recurrence after ileocolonic resection is common in Crohn’s disease. This randomized trial suggests vedolizumab can reduce early endoscopic recurrence, offering an additional biologic option for preventing...
Perianal fistula complications are serious and difficult to treat. This study suggests starting anti-TNFα therapy early in pediatric Crohn disease may substantially lower the risk of developing these complications,...
